Usana Health Sciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
USANA Health Sciences, Inc. reported a significant 74.4% decrease in net earnings for fiscal year 2025, despite an 8.3% increase in net sales driven by the Hiya acquisition, as its core nutritional business experienced a 14.8% decline in active customers.
NYSE
10-K: USANA Health Sciences Reports Lower 2024 Sales and Earnings Amidst Challenging Economic Conditions
USANA Health Sciences' 2024 results reveal a decrease in net sales and earnings, impacted by economic headwinds and currency fluctuations, despite strategic efforts including the acquisition of Hiya Health Products.
NYSE
USANA Health Sciences reported a decrease in net sales and earnings for 2023, while outlining its strategic focus on increasing active customers and expanding into new markets.